Aurinia Pharmaceuticals
AUPH
282 hedge funds and large institutions have $1.34B invested in Aurinia Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 105 increasing their positions, 80 reducing their positions, and 24 closing their positions.
108% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 24
31% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 80
22% more capital invested
Capital invested by funds: $1.1B → $1.34B (+$242M)
8% more funds holding
Funds holding: 260 → 282 (+22)
5.7% more ownership
Funds ownership: 55.66% → 61.36% (+5.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
61% less call options, than puts
Call options by funds: $10M | Put options by funds: $25.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$66.9M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
+$13.4M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$13M |
| 4 |
BlackRock
New York
|
+$5.55M |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$5.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$13.9M |
| 2 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$7.76M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$7.2M |
| 4 |
Jane Street
New York
|
-$6.64M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$4.98M |
AUPH Hedge Fund Activity: Q2 2026 in Review
282 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2026, worth a combined $1.34B — up 22% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new AUPH positions and 24 closed out — a net gain of 26 holders — while 105 added to existing stakes and 80 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $66.9M. The largest seller was Man Group, cutting an estimated $13.9M.
- 282 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2026, up from 260 in Q1 2026.
- Funds reported $1.34B of Aurinia Pharmaceuticals stock for Q2 2026, up 22% quarter-over-quarter.
- 50 funds opened new Aurinia Pharmaceuticals positions in Q2 2026 and 24 closed out, a net change of +26 holders.
- The largest Aurinia Pharmaceuticals buyer in Q2 2026 was Goldman Sachs, an estimated $66.9M added.
- The largest Aurinia Pharmaceuticals seller in Q2 2026 was Man Group, an estimated $13.9M sold.
Based on aggregated 13F filings for Q2 2026.